The Fosamax lawsuit landscape shifted dramatically in 2026, marking the most consequential year for plaintiffs since litigation began more than a decade ago. A cascade of legal and regulatory developments — a Supreme Court certiorari denial, a landmark Master Settlement Agreement, an FDA label expansion, and a California state settlement — has transformed what was once a frozen docket into an active resolution process affecting hundreds of injured patients. If you or a loved one took Fosamax (alendronate sodium) long-term and suffered an atypical femur fracture, understanding where this litigation stands in 2026 is essential.
What Is the Fosamax Lawsuit About?
Fosamax, Merck’s brand-name bisphosphonate drug prescribed to treat osteoporosis, works by slowing the rate at which the body breaks down old bone tissue. For many patients, this reduces the risk of common osteoporotic fractures. However, plaintiffs in MDL 2243 allege that long-term use suppresses bone remodeling so aggressively that microscopic stress cracks accumulate faster than the body can repair them — ultimately causing atypical femur fractures, a specific and serious type of break that occurs in the shaft or subtrochanteric region of the thigh bone.
Unlike ordinary osteoporotic fractures typically caused by falls, atypical femur fractures can happen during routine movements like walking or standing. They are often preceded by weeks or months of thigh or groin pain — a prodromal warning sign that, according to plaintiff advocates, Merck failed to adequately disclose. Bisphosphonates reduce bone turnover, which over time may leave bone unable to repair the tiny stress cracks that accumulate with everyday activity. You can review the pharmacological mechanism of bisphosphonates through publicly available resources at law.cornell.edu, which archives FDA drug labeling regulations under 21 CFR 201.57.
More than 4,000 lawsuits have been filed against Merck for Fosamax-related injuries in total. The current MDL 2243, formally titled In re: Fosamax Alendronate Sodium Products Liability Litigation No. II, focuses specifically on atypical femur fracture claims and is presided over by Judge Karen M. Williams in the District of New Jersey. For plaintiffs exploring what their injuries might be worth, a medical malpractice calculator can provide a general framework for understanding defective drug injury compensation ranges.
The Decade-Long Preemption Stalemate — And How It Ended in 2026
For years, the Fosamax lawsuit docket was effectively paralyzed by a single legal question: did federal law preempt state failure-to-warn claims? The argument centered on the FDA’s 2009 rejection of Merck’s proposed fracture warning language. Merck contended that because the FDA had already reviewed and declined a specific warning, it was legally impossible for the company to independently add a stronger state-law-compliant warning — triggering federal preemption and shielding it from liability.
That defense collapsed in stages. The Third Circuit reversed the preemption dismissal in September 2024, reinstating approximately 600 cases that had been thrown out. Merck then escalated to the United States Supreme Court, seeking certiorari. On June 16, 2025, the Supreme Court denied Merck’s certiorari petition, a ruling that permanently ended the preemption defense and reopened the litigation floodgates. This denial was the pivotal event that made the 2025 Master Settlement Agreement and the broader 2026 resolution process possible. The Supreme Court’s docket and orders are publicly accessible through supremecourt.gov.
The 2025 Master Settlement Agreement and 2026 Resolution Milestones
Within six weeks of the certiorari denial, Organon — the pharmaceutical company that spun off from Merck and assumed certain legacy drug liabilities — signed a Master Settlement Agreement on July 28, 2025. The MSA covers femur fracture claimants in both MDL 2243 and the parallel New Jersey state multicounty litigation (MCL). A critical condition of the MSA’s activation is that at least 95% of eligible plaintiffs must participate. Since the MSA’s execution, 413 cases have been resolved, demonstrating strong plaintiff uptake.
The financial terms of the MSA have not been publicly disclosed. For context, in a separate track involving osteonecrosis of the jaw (ONJ), Merck previously settled approximately 1,200 cases for $27.7 million total. It is worth noting that no jury verdict has ever been returned for a plaintiff alleging a Fosamax-caused femur fracture — every femur fracture case in the MDL was either dismissed on preemption grounds or resolved through settlement, which underscores why the MSA’s participation threshold matters so much to plaintiffs still in the queue.
On February 18, 2026, a California settlement agreement was executed, adding a state-level resolution layer to the broader litigation framework. Courts in New Jersey also issued an amended case management order in May 2026 requiring remaining plaintiffs to produce detailed documentation of drug use and injury history — with noncompliance risking dismissal. In March 2026, 17 cases were dismissed with prejudice, and additional cases were dismissed without prejudice in May 2026, reflecting continued active docket management by Judge Williams.
FDA Label Expansion: February 2026 Changes Every Current User Should Know
One of the most significant regulatory developments of 2026 occurred in February 2026, when the FDA expanded the Fosamax and alendronate label to address atypical fractures beyond the femur. The updated label notes that atypical fractures can occur in bones other than the thigh bone and that pain in other skeletal locations should prompt medical evaluation for potential stress fracture risk. This expansion is meaningful for two reasons: it acknowledges a broader injury profile than previously labeled, and it strengthens the scientific foundation underlying failure-to-warn arguments for plaintiffs whose fractures occurred outside the femur.
Alendronate (generic Fosamax) remains available by prescription in 2026, and the updated warnings now appear on current prescribing information. Patients who took the drug prior to these label updates — and suffered fractures the old label did not adequately warn against — may have preserved legal claims. The FDA’s drug labeling requirements and safety communication standards are governed by federal regulation; the CDC also maintains bone health data relevant to bisphosphonate use at cdc.gov.
MDL 2243 by the Numbers: Where the Litigation Stands in October 2026
The following table summarizes the current status of MDL 2243 and key Fosamax lawsuit milestones as of October 1, 2026:
| Metric | Data Point | Source / Date |
|---|---|---|
| Total cases filed in MDL 2243 | 1,294 | JPML Report, October 1, 2026 |
| Pending actions as of October 1, 2026 | 559 | JPML Report, October 1, 2026 |
| Cases resolved (overall resolution rate) | 735 cases resolved — 57% resolution rate | mdlupdate.com / JPML, 2026 |
| Cases resolved since MSA execution (July 2025) | 413 | mdlupdate.com, 2026 |
| MSA participation threshold required | 95% of eligible claimants | MSA terms, July 28, 2025 |
| Supreme Court cert denied | June 16, 2025 | U.S. Supreme Court Orders |
| FDA label expansion (atypical fractures beyond femur) | February 2026 | FDA / courtdocket.org, 2026 |
| California settlement agreement signed | February 18, 2026 | mdlupdate.com, 2026 |
| MDL formation year | 2011, Trenton Division, D.N.J. | drugwatch.com |
| Total Fosamax lawsuits filed (all tracks) | More than 4,000 | seegerweiss.com |
With 559 cases still pending as of October 1, 2026, and the 95% MSA participation threshold still driving resolution incentives, the Fosamax lawsuit docket remains actively contested. Plaintiffs who have not yet responded to documentation requirements face dismissal risk under the May 2026 case management order. Those who believe they have unresolved claims should act with urgency. Individuals with injuries from other defective pharmaceutical products may also benefit from reviewing a medical malpractice calculator to estimate potential compensation ranges before consulting qualified legal counsel.
Who May Still Have a Valid Fosamax Lawsuit Claim in 2026?
The Fosamax lawsuit primarily applies to patients who used Fosamax or generic alendronate for an extended period — typically three or more years — and subsequently suffered an atypical femur fracture or, in light of the February 2026 FDA label expansion, an atypical fracture in another bone. Qualifying fractures typically occur with low energy force, such as routine walking, and are distinct from the high-impact fractures associated with falls or trauma.
Potential claimants should gather prescription records documenting alendronate use, medical imaging (X-rays or MRI) showing the fracture location and pattern, and any records documenting prodromal pain — the thigh or groin discomfort that often precedes atypical fractures by weeks or months. In cases where a patient died as a result of fracture complications, surviving family members may have a wrongful death claim; a wrongful death calculator can help surviving families understand the financial dimensions of such claims. Statute of limitations deadlines vary by state, and with active dismissals occurring in the MDL throughout 2026, time is a critical factor for those who have not yet filed.
Frequently Asked Questions About the Fosamax Lawsuit in 2026
What is the current status of the Fosamax lawsuit MDL in 2026?
As of October 1, 2026, MDL 2243 — In re: Fosamax Alendronate Sodium Products Liability Litigation No. II — has 559 pending actions out of 1,294 total cases filed, representing a 57% resolution rate. The litigation is before Judge Karen M. Williams in the District of New Jersey. The July 28, 2025 Master Settlement Agreement has driven 413 resolutions since its signing, and a California settlement was finalized on February 18, 2026. The docket remains active, with ongoing case management orders requiring plaintiff documentation compliance. A July 10, 2026 analysis confirmed the litigation’s posture is resolution-focused, with the MSA driving most dispositions.
What injuries qualify for a Fosamax lawsuit claim?
The core qualifying injury in MDL 2243 is an atypical femur fracture — a low-energy break in the shaft or subtrochanteric region of the thigh bone often preceded by thigh or groin pain. These fractures differ from ordinary osteoporotic fractures because they occur during routine activity rather than a fall. In February 2026, the FDA expanded the Fosamax label to acknowledge that atypical fractures can occur in bones beyond the femur, potentially broadening the qualifying injury profile. Long-term use of Fosamax or generic alendronate — generally three or more years — is a key threshold criterion.
Why did the Supreme Court’s June 2025 cert denial matter so much for plaintiffs?
The Supreme Court’s denial of Merck’s certiorari petition on June 16, 2025 permanently ended the federal preemption defense that had frozen the Fosamax lawsuit docket for years. Merck had argued that because the FDA rejected its proposed fracture warning language in 2009, federal law preempted state failure-to-warn claims — effectively making it legally impossible for Merck to face liability under state law. The Third Circuit had rejected this argument in September 2024, reinstating approximately 600 cases. When the Supreme Court declined to hear Merck’s appeal, it cemented that ruling, allowing the Master Settlement Agreement and active resolution process to proceed.
How much money could a Fosamax lawsuit settlement be worth?
The financial terms of the July 2025 Master Settlement Agreement covering femur fracture claimants in MDL 2243 have not been publicly disclosed. In a separate track involving osteonecrosis of the jaw (ONJ), Merck settled approximately 1,200 cases for $27.7 million total. Individual settlement values in mass tort litigation typically vary based on injury severity, duration of drug use, medical expenses, lost income, and other damages. No jury verdict has ever been returned for a plaintiff in the femur fracture track — every resolved case has been settled. A personal injury settlement calculator can help claimants understand the general factors that influence settlement ranges in pharmaceutical injury litigation.
Is it too late to file a Fosamax lawsuit in 2026?
It depends on your individual circumstances, including your state of residence and when your injury occurred or was diagnosed. Statutes of limitations for pharmaceutical product liability claims typically range from two to six years depending on the state, and many states apply a “discovery rule” that starts the clock when you knew or should have known your fracture was linked to drug use. With active dismissals occurring in the MDL throughout 2026 — including 17 cases dismissed with prejudice in March 2026 — and documentation compliance deadlines set by the May 2026 case management order, urgency is real. The February 2026 FDA label expansion may also affect when the discovery clock begins for newly identified injury types.
Legal disclaimer: This article is provided for general informational purposes only and does not constitute legal advice; readers should consult a licensed attorney in their jurisdiction regarding the specific facts of their potential Fosamax lawsuit claim.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.